Canadian Halal Investor.

NASDAQ Shariah screener · October 2026

Is BridgeBio Pharma, Inc. (BBIO) Halal?

PASS

BridgeBio Pharma, Inc. · NASDAQ: BBIO · Healthcare

The short answer

BridgeBio Pharma passes all three Shariah gates: it develops and sells medicines for genetic diseases (no interest-based business), carries about $2.71B of interest-bearing obligations (21.0% of its ~$12.92 billion market cap), and separately disclosed interest income of about 3.95% of revenue is under the 5% ceiling.

Gate 1 — Business activity: PASS

Gate 1 — business activity: PASS. BridgeBio Pharma, Inc., per its FY2025 Form 10-K (year ended December 31, 2025), is a commercial-stage biopharmaceutical company 'founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.' Its lead commercial product is Attruby (acoramidis), approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), alongside a pipeline of genetic-medicine candidates in clinical and preclinical development.

The company is not an interest-based lender and is not involved in tobacco, gambling, pork, or conventional banking or insurance. Its convertible notes and deferred royalty obligations are financing instruments, not interest-based business lines, and its 2025 net loss of $732.9 million reflects heavy research and development investment — ordinary for a commercial-stage biotech, not a haram business line. The business passes gate 1.

Gate 2 — Debt and cash: PASS

Gate 2 — interest-bearing debt: PASS (21.0%, ceiling 33%). Per BridgeBio Pharma's FY2025 Form 10-K balance sheet at December 31, 2025, the company carried convertible notes (net) of $1,852.5 million — 2031 Notes $564.6 million, 2029 Notes $740.9 million, 2027 Notes $547.0 million — plus deferred royalty obligations, net, of $855.0 million, financing obligations that accrue interest (noncash interest expense of $125.1 million in 2025). Total interest-bearing obligations: about $2,707.5 million. Notes-only debt would be about $1,852.5 million (14.3% of market cap); operating lease liabilities ($18.7 million) are excluded.

$2,707.5 million against a market capitalization of about $12.92 billion (Finnhub, live quote October 2, 2026; MarketBeat reported $13.08 billion the same day) is about 21.0% — under the 33% ceiling. For transparency, the company issued 2033 convertible notes in Q1 2026 ($619.6 million net at March 31, 2026); pro-forma obligations would be about 25.8% of market cap — still under the ceiling.

Gate 3 — Non-compliant income: PASS

Gate 3 — non-compliant income: PASS (3.95%, ceiling 5%). BridgeBio Pharma's FY2025 Form 10-K separately discloses interest income on its own line in the Consolidated Statements of Operations: $19,854 thousand against total revenues, net, of $502,076 thousand is about 3.95% — under the 5% ceiling (2024: $17,249 thousand; 2023: $18,038 thousand).

This is the closest of the gates for BridgeBio but it clears the threshold; the most recent annual figure (3.95%) is used for this gate.

Key figures used

Frequently asked questions

What does BridgeBio Pharma do?

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a commercial-stage biopharmaceutical company founded in 2015 to discover, create, test, and deliver transformative medicines for patients with genetic diseases. Per its FY2025 Form 10-K (year ended December 31, 2025), its lead commercial product is Attruby (acoramidis), approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), alongside a pipeline of genetic-medicine candidates in clinical and preclinical development. Total revenues, net, were $502,076 thousand in 2025 - $362,368 thousand net product revenue, $128,322 thousand license and services revenue, and $11,386 thousand royalty revenue.

Is BridgeBio Pharma's business Shariah compliant?

BridgeBio Pharma discovers, develops, and sells prescription medicines for genetic diseases - it is not an interest-based lender and is not involved in tobacco, gambling, pork, or conventional banking or insurance. Its convertible notes and deferred royalty obligations are financing instruments, not interest-based business lines. The company reported a net loss of $732,938 thousand in 2025 as it invests heavily in research and development - ordinary for a commercial-stage biotech, not a haram business line. Assessed on the filed business description, the business passes this screener's first gate.

How much interest-bearing debt does BridgeBio Pharma have?

BridgeBio Pharma's balance sheet at December 31, 2025 (FY2025 Form 10-K) shows convertible notes with a net carrying amount of $1,852.5 million (2031 Notes $564.6 million, 2029 Notes $740.9 million, 2027 Notes $547.0 million) plus deferred royalty obligations, net, of $855.0 million - financing obligations that accrue interest - for total interest-bearing obligations of about $2,707.5 million. (Notes-only debt would be about $1,852.5 million, or 14.3% of market cap.) $2,707.5 million against a market capitalization of about $12.92 billion (Finnhub, live quote October 2, 2026; MarketBeat reported $13.08 billion the same day) is about 21.0% - under the 33% ceiling. For transparency: the company issued 2033 convertible notes in Q1 2026 ($619.6 million net at March 31, 2026), which would put pro-forma obligations at about 25.8% of market cap - still under the ceiling. Interest expense was $53.1 million in 2025, plus $125.1 million of noncash interest on the deferred royalty obligations.

How much interest income does BridgeBio Pharma earn?

BridgeBio Pharma's FY2025 Form 10-K separately discloses interest income on its own line in the Consolidated Statements of Operations: $19,854 thousand against total revenues, net, of $502,076 thousand is about 3.95% - under the 5% non-compliant income ceiling (2024: $17,249 thousand; 2023: $18,038 thousand). This is the closest of this screener's gates for BridgeBio but still clears the threshold. Cash, cash equivalents, and marketable securities of $587.5 million at December 31, 2025 represent about 4.5% of market capitalization.

What do third-party Shariah screeners say about BridgeBio Pharma?

Zoya publishes a BBIO page under its AAOIFI methodology; its September 2026 update indicates Shariah-compliant. Zoya cites the same FY2025 figures ($19,854,000 interest income against $502,078,000 revenue, about 3.95%). I could not verify a Musaffa rating page for BBIO or a ShariaPortfolio rating from public sources. Third-party screeners apply different assumptions and update on different schedules, and their results can change when new financial statements are published - always check the latest screening before investing.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).